Lung (non-small cell) cancer Cancer Lung (non-small cell)
Conditions
Interventions
All patients receive chemotherapy with MVP (mitomycin-C, vinblastine and moderate dose cisplatin) repeated every 21 days for three courses. Mitomycin-C in given with the first and second course only.
Sponsors
The Royal Marsden NHS Foundation Trust (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histological evidence of non-small cell lung cancer 2. Stage IIIb or IV disease not eligible for neoadjuvant chemotherapy and/or radical radiotherapy 3. Performance status <2 (Zubrod-Eastern Cooperative Oncology Group [ECOG]-World Health Organisation [WHO] scale) 4. Adequate renal, bone marrow, and lung function tests unless due to metastatic disease 5. Patients must already have achieved symptom relief after three cycles of MVP chemotherapy 6. No uncontrolled infection 7. No previous conventional chemotherapy prior to MVP. One prior phase I/II new drug is allowed 8. No medical contraindications to treatment protocols
Exclusion criteria
Exclusion criteria: Not provided at time of registration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed